NEWS RELEASE, 27 OCTOBER 2021

EVOTEC SE: TRANSLATIONAL BRIDGE
beLAB2122 IN COLLABORATION WITH BRISTOL MYERS SQUIBB IDENTIFIES FIRST PROJECT

FIRST PROJECT ORIGINATES FROM THE GERMAN CANCER RESEARCH CENTER ("DKFZ") AND HEIDELBERG UNIVERSITY IN HEIDELBERG
beLAB2122 IS A TRANSLATIONAL BRIDGE COLLABORATION BETWEEN EVOTEC AND BRISTOL MYERS SQUIBB

Hamburg, Germany, 27 October 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the first project to be developed within beLAB2122, a collaboration between Evotec and Bristol Myers Squibb. beLAB2122 aims to bring together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. After signing the beLAB2122 collaboration agreement in April 2021, the first project to be developed within this academic BRIDGE collaboration has now been nominated.

Originating in the laboratory of Dr Darjus Tschaharganeh, Group Leader at the German Cancer Research Center (“DKFZ”), Heidelberg, and Professor at Heidelberg University, the project is based on the observation of synthetic lethal interactions in certain cancer types and aims at the development of small molecule inhibitors of a nutrient transporter essential for the survival of these cancer cells.

beLAB2122 will now leverage Evotec’s integrated discovery and development platform to validate and develop the project further. The goal of beLAB2122 is to develop academic projects to value inflection points that allow the formation of new jointly owned spin-off companies.

Dr Thomas Hanke, EVP & Head of Academic Partnerships at Evotec, commented: “We are pleased to further explore the promising approach from the DKFZ and Heidelberg University as the first funded project of beLAB2122. Evotec’s BRIDGE collaborations aim at seamlessly integrating academic innovations into the pharmaceutical value chain and accelerating them to new company formations. We look forward to progressing this and many more interesting academic projects using

For further information, please contact: Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, gabriele.hansen@evotec.com, T. +49.(0)40.560 81-255, F. +49.(0)40.560 81-333, www.evotec.com
Evotec’s highly efficient integrated drug discovery & development infrastructure called the ‘Data-driven R&D Autobahn to Cures’ At the same time, we are pleased to receive additional promising applications from scientists working within the beLAB2122 member institutions at the EMBL, the German Cancer Research Center, the Goethe University Frankfurt, Heidelberg University and Tübingen University, and are looking forward to expanding the scope of the project portfolio further.”

Dr Darjus Tschaharganeh, Group Leader at the German Cancer Research Center (DKFZ) and Professor at Heidelberg University, added: “We are excited to be chosen as the first beLAB2122 project and to be part of the collaboration bridge. Our project evolved from fundamental basic research and we are now at a point that our results clearly illustrate that pharmacological inhibitors for this target could be very successful for cancer treatment. The beLAB2122 initiative with strong pharmaceutical partners is ideally suited to pursue this project. We are looking forward to a close interaction with Evotec and Bristol Myers Squibb and hope that we can find potent inhibitors for our target in order to get to the next step and hopefully will be able to bring this in the future to the clinics for the benefit of patients.”

beLAB2122 is backed by Evotec in collaboration with Bristol Myers Squibb. The total volume of US$ 20 m will allow for several more funding rounds. For more information on beLAB2122, visit www.belab2122.org.

About Evotec’s BRIDGE model: Partnering to accelerate innovation
Evotec has created a new paradigm to translate early-stage academic research to drug discovery and development called “BRIDGE” (Biomedical Research, Innovation & Development Generation Efficiency), an integrated fund and award framework to tap into academic science to accelerate the formation of spin-out companies and generate collaborations with Pharma and biotech. Through these efforts, Evotec has defined a new formula for fast-track early-stage drug discovery. Since the launch of the BRIDGE model in 2016, Evotec has formed and funded a number of different collaborations, e.g. LAB282, LAB150, LAB031, LAB10x, Autobahn Labs, Argobio and Danube-Labs. Please visit www.evotec.com/en/innovate/bridges to learn more about Evotec’s BRIDGEs.

ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and
within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.